| Trial ID: | L1197 |
| Source ID: | NCT00967993
|
| Associated Drug: |
Ferric Citrate
|
| Title: |
Trial of a New Formulation of KRX-0502 (Ferric Citrate) in Patients With End-Stage Renal Disease
|
| Acronym: |
|
| Status: |
COMPLETED
|
| Study Results: |
YES
|
| Results: |
https://ClinicalTrials.gov/show/NCT00967993/results
|
| Conditions: |
Hyperphosphatemia|End-stage Renal Disease|Renal Failure Chronic Requiring Hemodialysis
|
| Interventions: |
DRUG: ferric citrate
|
| Outcome Measures: |
Primary: The Primary Outcome of This Trial Will be the Change in Serum Phosphorus From Baseline to End of Treatment After a Four Week Treatment Period., 4 weeks | Secondary: The Incidence of Treatment-emergent Adverse Events (New or Worsened From Study Drug Initiation) Will be Summarized by Body System, Severity, Type of Adverse Event, and Presumed Relationship to the Study Drug., 6 weeks
|
| Sponsor/Collaborators: |
Sponsor: Keryx Biopharmaceuticals
|
| Gender: |
ALL
|
| Age: |
ADULT, OLDER_ADULT
|
| Phases: |
|
| Enrollment: |
22
|
| Study Type: |
OBSERVATIONAL
|
| Study Designs: |
Observational Model: |Time Perspective: p
|
| Start Date: |
2010-01
|
| Completion Date: |
2010-05
|
| Results First Posted: |
2014-11-18
|
| Last Update Posted: |
2014-12-05
|
| Locations: |
Barzilai Medical Center Ben-Gurion University, Ashkelon, 78306, Israel|Hadassah University Hospital-Ein Kerem, Jerusalem, 91120, Israel|Assaf Haraofeh Medical Center, Zerifin, 70300, Israel
|
| URL: |
https://clinicaltrials.gov/show/NCT00967993
|
